They found that MASH-related histologic changes and noninvasive test responses (including histologic resolution of MASH without worsening of liver fibrosis, ALT responses, and FibroScan AST [FAST] responses), as well as fibrosis-related histologic improvement and noninvasive test responses (including improvement in fibrosis without worsening of MASH, VCTE responses, and ELF score responses), were greater in patients receiving semaglutide than in patients receiving placebo, even at a similar amount of weight reduction
We will also review factors that may make GLP1 therapy inappropriate or require extra caution, including: Medical Weight Loss, Tailored to You Your visit starts with a straightforward medical evaluation: health history, current medications, prior weightloss attempts, and what success actually looks like for you
That is one reason this should never be framed as a simple consumer choice between pill and shot. It is still a real medical decision that should account for medical history, side effects, medication tolerance, and the larger metabolic picture
Results and conclusions The researchers screened 709 participants between September 13 and November 22, 2021, of which the researchers randomly assigned 334 and 333 participants to oral semaglutide 50 mg and placebo groups, respectively, comprising the cumulative intention-to-treat analysis group
